NCCN practice guidelines for early detection of prostate cancer

ONCOLOGY

Volumn 13, Issue 11 A, 1999, Pages 99-114

  Potter, Steven R ^a   Partin, Alan ^b  

^a Department of Urology ^*  (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008033112     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. General Information on Prostate Cancer Babaian RJ, Miyashita H, Evans RB, et al: Early detection program for prostate cancer: Results and identification of high-risk patient population. Urology 37:193-197, 1991.
2. Catalona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements. JAMA 277:1452-1460, 1997.
3. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tic) prostate cancer. JAMA 271:368-374, 1994.
4. Herschman JD, Smith DS, Catalona WJ: Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 50:239-243, 1997.
5. Jacobsen SJ, Bergstralh EJ, Katusic SK, et al: Screening digital rectal examination and prostate cancer mortality: A population-based case-control study. Urology 52:173-179, 1988.
6. Morgan TO, Jacobsen SJ, McCarthy WF, et al: Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med 335:304-309, 1996.
7. Moul JW, Connelly RR, Mooneyhan RM, et al: Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol 162:394-397.
8. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 270:860-864, 1993.
9. Scardino FT, Moul JW, Melman A: Prostate cancer in African-American men: Is it a preventable epidemic? Professional Connection 2 (2): 1996.
10. Seaman EK, Whang IS, Cooner W, et al: Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate. Urology 43:645-648, 1994.
11. Stenner J, Holthaus K, Mackenzie SH, et al: The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population. Urology 51:455-459, 1998.
12. Ukimura O, Durrani O, Babaian RJ: Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology 50:66-72, 1997.
13. von Eschenbach A, Ho R, Murphy GP, et al: American Cancer Society guideline for the early detection of prostate cancer: Update 1997. CA Cancer J Clin 47:261-264, 1997.
14. Walsh PC, Partin AW: Family history facilitates the early diagnosis of prostate carcinoma. Cancer 80:1871-1874, 1997.
15. Witte MN, Morton RA: Prostate cancer in high-risk groups: Searching for explanations. Contemporary-Urology 9:62-70, 1997.
16. Carter HB, Epstein JI, Chan DW, et al: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277:1456-1460, 1997.
17. Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. J Urol 152:2037-2042, 1994.
18. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161, 1991.
19. Cooner WH, Mosley BR, Rutherford CL Jr, et al: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination, and prostate specific antigen. J Urol 143:1146-1154, 1990.
20. Polascik TJ, Oesterling JE, Partin AW: Prostate-specific antigen: A decade of discovery -what we have learned and where we are going? J Urol 162:293-306, 1999.
21. Catalona WJ, Partin AW, Slawin KM, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 279:1542-1547, 1998.
22. Luderer AA, Chen Y-T, Soriano TF, et al: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antisen. Urology 26:187-194, 1995.
23. Partin AW, Brawer MK, Subong ENP, et al: Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer and Prostatic Diseases 1:197-203, 1998.
24. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992.
25. Gormley GJ, Ng J, Cook T, et al: Effect of finasteride on prostate-specific antigen density. Urology 43:53-59, 1994.
26. Guess HA, Gormley GJ, Stoner E, et al: The effect of finasteride on prostate specific antigen: Review of available data. J Urol 155:3-9, 1996.
27. Allen EA, Kahane H, Epstein JI: Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy. Urology 53:1179-1183, 1999.
28. Bostwick DG: Evaluating needle biopsy: Therapeutic and prognostic importance. CA Cancer J Clin 47:297-319, 1997.
29. Bostwick DG: Precursor lesions in urologic pathology: Prostate, bladder, and kidney, Lesson 13. AUA Update Series 17, 1998.
30. Chan TY, Epstein JI: Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 53:351-355, 1999.
31. Chang JJ, Shinohara K, Hovey RM, et al: Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection. Urology 52:89-93, 1998.
32. Chan TY, Epstein JI: Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 53:351-355, 1999.
33. Chen ME, Troncoso P, Johnston DA, et al: Optimization of prostate biopsy strategy using computer based analysis. J Urol 158:2168-2175, 1997.
34. Levine MA, Ittman M, Melamed J, et al: Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 159:471-475, 1998.
35. Miller DC, Naughton CK, Mager DE, et al: Prospective randomized trial comparing 6 vs 12 cores: Effect on cancer detection rate (abstract). J Urol 161:290, 1999.